Transplantation of iPS stem cells in the brain with Parkinson's disease


A group of Japanese researchers announced on Friday that transplanted pluripotent stem cells (iPS) in the brain of a patient with Parkinson's disease, the first related testing in the world.

A team from the Kyoto University has injected 2.4 million iPS cells –capable of creating all types of cells– in the left part of the brain in the three-hour operation in October.

A man aged 50, He is well spent on treatment and will remain under control for two years, said the Kyoto University in a statement.

If there are problems in the next six months, researchers will implant 2.4 million additional cells, this time in the right part of the brain.

These iPS healthy-donor cells should develop into dopamine-producing neurons, a neurotransmitter involved in engine monitoring.

In July, the Kyoto University announced that it will conduct a clinical trial with seven people aged 50 to 69 years.

Parkinson's disease is typical neuronal degeneration, with symptoms that are gradually worsening, such as trembling, muscle stiffness and loss of body physical ability.

This affects more than ten million people worldwide, according to American Parkinson's Foundation Disease. Currently available therapy "improves symptoms without slowing the progression of the disease," explains the foundations.

New inquiries focus on redirecting evil.

Prior to clinical trials in humans, an experiment was carried out in monkeys with human stem cells that improved the mobility of primates affected by a variety of Parkinson's disease, according to a study published in the science journal Nature at the end of August 2017.

For two years, the survival rate of transplanted cells was accurately controlled by injection in the brain of the primates and no tumor was detected.

Indurane pluripotent stem cells (iPS) are adult cells that are reduced to an almost embryonic state to produce four genes (usually inactive in adults). This genetic manipulation returns the ability to make any cell according to the place where the body is transplanted.

The use of iPS cells does not present important ethical problems, unlike stem cells derived from human embryos.

Source link